These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1870211)

  • 41. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique.
    Roca A; Abacassamo F; Loscertales MP; Quintó L; Gómez-Olivé X; Fenwick F; Saiz JC; Toms G; Alonso PL
    J Med Virol; 2002 Aug; 67(4):616-23. PubMed ID: 12116014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus.
    Nicholas JA; Mitchell MA; Levely ME; Rubino KL; Kinner JH; Harn NK; Smith CW
    J Virol; 1988 Dec; 62(12):4465-73. PubMed ID: 2460636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
    Belshe RB; Anderson EL; Walsh EE
    J Infect Dis; 1993 Oct; 168(4):1024-9. PubMed ID: 8376814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.
    Chargelegue D; Obeid OE; Hsu SC; Shaw MD; Denbury AN; Taylor G; Steward MW
    J Virol; 1998 Mar; 72(3):2040-6. PubMed ID: 9499058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response.
    Akerlind-Stopner B; Utter G; Norrby E; Mufson MA
    J Med Virol; 1995 Oct; 47(2):120-5. PubMed ID: 8830114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.
    Anderson LJ; Bingham P; Hierholzer JC
    J Virol; 1988 Nov; 62(11):4232-8. PubMed ID: 2459412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection.
    Chiba Y; Higashidate Y; Suga K; Honjo K; Tsutsumi H; Ogra PL
    J Med Virol; 1989 Jul; 28(3):133-9. PubMed ID: 2666570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinetics of antibody-induced modulation of respiratory syncytial virus antigens in a human epithelial cell line.
    Sarmiento RE; Tirado RG; Valverde LE; Gómez-Garcia B
    Virol J; 2007 Jul; 4():68. PubMed ID: 17608950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of immunoglobulin E-specific antibodies and viral antigens in nasopharyngeal secretions of children with respiratory syncytial virus infections.
    Russi JC; Delfraro A; Borthagaray MD; Velazquez B; García-Barreno B; Hortal M
    J Clin Microbiol; 1993 Apr; 31(4):819-23. PubMed ID: 8463392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
    Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of respiratory syncytial virus (RSV) antigen in the lungs of guinea pigs 6 weeks after experimental infection and despite of the production of neutralizing antibodies.
    Streckert HJ; Philippou S; Riedel F
    Arch Virol; 1996; 141(3-4):401-10. PubMed ID: 8645083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody response to respiratory syncytial virus structural proteins in children with acute respiratory syncytial virus infection.
    Vainionpää R; Meurman O; Sarkkinen H
    J Virol; 1985 Mar; 53(3):976-9. PubMed ID: 3973971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.
    Murphy BR; Alling DW; Snyder MH; Walsh EE; Prince GA; Chanock RM; Hemming VG; Rodriguez WJ; Kim HW; Graham BS
    J Clin Microbiol; 1986 Nov; 24(5):894-8. PubMed ID: 3771779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.
    Openshaw PJ; Anderson K; Wertz GW; Askonas BA
    J Virol; 1990 Apr; 64(4):1683-9. PubMed ID: 2319650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.
    Taylor G; Stott EJ; Furze J; Ford J; Sopp P
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2217-23. PubMed ID: 1383403
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The production of monoclonal antibodies against respiratory syncytial virus and its clinical applications.
    Wu B
    Clin Lab Med; 1985 Sep; 5(3):589-613. PubMed ID: 3899483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for the role of glycoprotein G of respiratory syncytial virus in binding of Neisseria meningitidis to HEp-2 cells.
    Raza MW; Blackwell CC; Ogilvie MM; Saadi AT; Stewart J; Elton RA; Weir DM
    FEMS Immunol Med Microbiol; 1994 Nov; 10(1):25-30. PubMed ID: 7874075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes.
    Levely ME; Bannow CA; Smith CW; Nicholas JA
    J Virol; 1991 Jul; 65(7):3789-96. PubMed ID: 1710289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.